The effect of acute hypoxia on excitability in the heart and the L-type calcium channel as a therapeutic target

Current Drug Discovery Technologies

Volumn 5, Issue 4, 2008, Pages 302-311

  Macdonald, William A ^a   Hool, Livia C ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Anti arrhythmic therapy; Arrhythmias; Early afterdepolarizations; Hypoxia; L type Ca2+ channel; Reactive oxygen species; Redox

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DILTIAZEM; HYDROGEN PEROXIDE; NIFEDIPINE; POTASSIUM CHANNEL; REACTIVE OXYGEN METABOLITE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; SODIUM PROTON EXCHANGE PROTEIN; VERAPAMIL;

ARRHYTHMOGENESIS; CALCIUM MOBILIZATION; CHANNEL GATING; CONSTIPATION; DRUG TARGETING; FLUID RETENTION; HEART ARRHYTHMIA; HEART MUSCLE EXCITABILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HUMAN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; REVIEW; SIDE EFFECT; SODIUM CALCIUM EXCHANGE;

ACTION POTENTIALS; ACUTE DISEASE; ANIMALS; ANOXIA; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; HEART; ION CHANNELS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 57349101002     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016308786733546     Document Type: Review

References (112)

1. Keating M.T., Sanguinetti M.C.: Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104, 569, 2001.
2. Kolar F., Ostadal B.: Molecular mechanisms of cardiac protection by adaptation to chronic hypoxia. Physiol. Res. 53, S3, 2004.
3. Dhalla N.S., Temsah R.M., Netticadan T.: Role of oxidative stress in cardiovascular diseases. J. Hypertens. 18, 655, 2000.
4. Williams S.E., Wootton P., Mason H.S., Bould J., Iles D.E., Riccardi D., Peers C., Kemp P.J.: Hemoxygenase-2 is an oxygen sensor for a calciumsensitive potassium channel. Science 306, 2093, 2004.
5. Casey T.M., Pakay J.L., Guppy M., Arthur P.G.: Hypoxia causes downregulation of protein and RNA synthesis in noncontracting Mammalian cardiomyocytes. Circ. Res. 90, 777, 2002.
6. Lopez-Barneo J., Pardal R., Ortega-Saenz P.: Cellular mechanism of oxygen sensing. Annu. Rev. Physiol. 63, 259, 2001.
7. Finkel T.: Oxygen radicals and signaling. Curr. Opin. Cell Biol. 10, 248, 1998.
8. Hool L.C., Corry B.: Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxid Redox Signal 9, 409, 2007.
9. Takahashi N., Hirose M.: Determination of sulfhydryl groups and disulfide bonds in a protein by polyacrylamide gel electrophoresis. Anal. Biochem. 188, 359, 1990.
10. Duranteau J., Chandel N.S., Kulisz A., Shao Z., Schumacker P.T.: Intracellular signaling by reactive oxygen species during hypoxia in cardiomyocytes. J. Biol. Chem. 273, 11619, 1998.
11. Vanden Hoek T., Becker L.B., Shao Z.H., Li C.Q., Schumacker P.T.: Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ. Res. 86, 541, 2000.
12. Budinger G.R., Chandel N., Shao Z.H., Li C.Q., Melmed A., Becker L.B., Schumacker P.T.: Cellular energy utilization and supply during hypoxia in embryonic cardiac myocytes. Am. J. Physiol. 270, L44, 1996.
13. Ferrari R.: The role of mitochondria in ischemic heart disease. J. Cardiovasc. Pharmacol. 28, S1, 1996.
14. Hanson E.S., Leibold E.A.: Regulation of iron regulatory protein 1 during hypoxia and hypoxia/reoxygenation. J. Biol. Chem. 273, 7588, 1998.
15. Hool L.C., Arthur P.G.: Decreasing cellular hydrogen peroxide with catalase mimics the effects of hypoxia on the sensitivity of the L-type Ca2+ channel to beta-adrenergic receptor stimulation in cardiac myocytes. Circ. Res. 91, 601, 2002.
16. Kroll S.L., Czyzyk-Krzeska M.F.: Role of H2O2 and heme-containing O2 sensors in hypoxic regulation of tyrosine hydroxylase gene expression. Am. J. Pysiol. 274, C167, 1998.
17. Ganitkevich V., Reil S., Schwethelm B., Schroeter T., Benndorf K.: Dynamic responses of single cardiomyocytes to graded ischemia studied by oxygen clamp in on-chip picochambers. Circ. Res. 99, 165, 2006.
18. Griendling K.K., Sorescu D., Ushio-Fukai M.: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86, 494, 2000.
19. Li J.M., Gall N.P., Grieve D.J., Chen M., Shah A.M.: Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40, 477, 2002.
20. Hool L.C., Di Maria C.A., Viola H.M., Arthur P.G.: Role of NAD(P)H oxidase in the regulation of cardiac L-type Ca2+ channel function during acute hypoxia. Cardiovasc. Res. 67, 624, 2005.
21. Hool L.C.: Reactive oxygen species in cardiac signalling: from mitochondria to plasma membrane ion channels. Clin. Exp. Pharmacol. Physiol. 33, 146, 2006.
22. Wang W., Ma J., Zhang P., Luo A.: Redox reaction modulates transient and persistent sodium current during hypoxia in guinea pig ventricular myocytes. Pflugers. Arch. 454, 461, 2007.
23. Coronel R., Fiolet J.W., Wilms-Schopman J.G., Opthof T., Schaapherder A.F., Janse M.J.: Distribution of extracellular potassium and electrophysiologic changes during two-stage coronary ligation in the isolated, perfused canine heart. Circulation 80, 165, 1989.
24. Kuroko Y., Yamazaki T., Tokunaga N., Akiyama T., Kitagawa H., Ishino K., Sano S., Mori H.: Cardiac epinephrine synthesis and ischemia-induced myocardial epinephrine release. Cardiovasc. Res. 74, 438, 2007.
25. Hesketh J.C., Herrera D., Zicha S., Nattel S.: Novel targets for cardiac antiarrhythmic drug development. Curr. Pharm. Des. 11, 1959, 2005.
26. 2+ current. Circ. Res. 64, 977, 1989.
27. Marban E., Robinson S.W., Wier W.G.: Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J. Clin. Invest. 78, 1185, 1986.
28. Volders P.G., Kulcsar A., Vos M.A., Sipido K.R., Wellens H.J., Lazzara R., Szabo B.: Similarities between early and delayed afterdepolarizations induced by isoproterenol in canine ventricular myocytes. Cardiovasc. Res. 34, 348, 1997.
29. Schomig A., Fischer S., Kurz T., Richardt G., Schomig E.: Nonexocytotic release of endogenous noradrenaline in the ischemic and anoxic rat heart: mechanism and metabolic requirements. Circ. Res. 60, 194, 1987.
30. Belardinelli L., Shryock J.C., Song Y., Wang D., Srinivas M.: Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J. 9, 359, 1995.
31. Belardinelli L., Isenberg G.: Actions of adenosine and isoproterenol on isolated mammalian ventricular myocytes. Circ. Res. 53, 287, 1983.
32. Srinivas M., Song Y., Shyrock J., Belardinelli L.: Cardiac Electrophysiological Actions of Adenosine. Drug Develop. Resear. 45, 420, 1998.
33. Mubagwa K., Mullane K., Flameng W.: Role of adenosine in the heart and circulation. Cardiovasc. Res. 32, 797, 1996.
34. Zimmer H.G., Trendelenburg C., Kammermeier H., Gerlach E.: De novo synthesis of myocardial adenine nucleotides in the rat. Acceleration during recovery from oxygen deficiency. Circ. Res. 32, 635, 1973.
35. Maier S.K., Westenbroek R.E., Schenkman K.A., Feigl E.O., Scheuer T., Catterall W.A.: An unexpected role for brain-type sodium channels in coupling of cell surface depolarization to contraction in the heart. Proc. Natl. Acad. Sci. USA 99, 4073, 2002.
36. Carmeliet E.: Slow inactivation of the sodium current in rabbit cardiac Purkinje fibres. Pflugers Arch. 408, 18, 1987.
37. Haigney M.C., Lakatta E.G., Stern M.D., Silverman H.S.: Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading. Circulation 90, 391, 1994.
38. (+) exchanger is critical to reperfusion damage and preconditioning in the isolated rat heart. Cardiovasc. Res. 48, 244, 2000.
39. Ju Y.K., Saint D.A., Gage P.W.: Hypoxia increases persistent sodium current in rat ventricular myocytes. J. Physiol. 497, 337, 1996.
40. Hammarstrom A.K., Gage P.W.: Inhibition of oxidative metabolism increases persistent sodium current in rat CA1 hippocampal neurons. J. Physiol. 510, 735, 1998.
41. (+) current during cardiac ischemia and hypoxia. J. Cardiovasc. Electrophysiol. 17, S96, 2006.
42. Noble D., Noble P.J.: Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 92, iv1, 2006.
43. + channels. Physiol. Rev. 85, 33, 2005.
44. Abbott G.W.: Molecular mechanisms of cardiac voltage-gated potassium channelopathies. Curr. Pharm. Des. 12, 3631, 2006.
45. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96, 195, 1990.
46. + channels in rat ventricular myocytes. J. Mol. Cell Cardiol. 34, 1623, 2002.
47. + channels by hypoxia. J. Physiol. 554, 743, 2004.
48. + conductance during metabolic inhibition by cyanide in guinea pig ventricular myocytes. Nippon Ika Daigaku Zasshi 57, 308, 1990.
49. Piao L., Li J., McLerie M., Lopatin A.N.: Transgenic upregulation of I(K1) in the mouse heart is proarrhythmic. Basic Res. Cardiol. 5, 5, 2007.
50. + channels by hypoxia in rabbit coronary arterial smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 289, H2461, 2005.
51. 2+ exchange of isolated sarcolemmal membrane: effects of insulin, oxidants and insulin deficiency. Mol. Cell Biochem. 83, 15, 1988.
52. 2+ exchanger in hypoxic reoxygenated guinea pig ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 286, H955, 2004.
53. Noble D.: Simulation of Na/Ca exchange activity during ischemia. Ann. NY Acad. Sci. 976, 431, 2002.
54. Rodriguez B., Trayanova N., Noble D.: Modeling cardiac ischemia. Ann. NY Acad. Sci. 1080, 395, 2006.
55. Murphy A.J.: Sulfhydryl group modification of sarcoplasmic reticulum membranes. Biochemistry 15, 4492, 1976.
56. (2+)-pump dysfunction in rat cardiomyocytes briefly exposed to hydroxyl radicals. Free Radic. Biol. Med. 22, 37, 1997.
57. 2+-ATPase. Arch. Biochem. Biophys. 246, 589, 1986.
58. (2+) release in permeabilized rat ventricular myocytes. J. Physiol. 555, 727, 2004.
59. Bers D.M., Excitation-contration coupling and cardiac contractile force. Second Ed., Dordrecht: Kluwer Academic Publishers, 2001.
60. 2+-pump activity by oxygen free radicals. Am. J. Physiol. 256, H368, 1989.
61. 2+ pump by oxygen free radicals. Am. J. Physiol. 257, H804, 1989.
62. Boldyrev A., Kurella E.: Mechanism of oxidative damage of dog kidney Na/K-ATPase. Biochem. Biophys. Res. Commun. 222, 483, 1996.
63. +-ATPase. Am. J. Physiol. 252, H252, 1987.
64. (+)-ATPase: inactivation by neutrophil-derived free radicals and oxidants. Am. J. Physiol. 259, H1330, 1990.
65. Xie Z.J., Wang Y.H., Askari A., Huang W.H., Klaunig J.E., Askari A.: Studies on the specificity of the effects of oxygen metabolites on cardiac sodium pump. J. Mol. Cell Cardiol. 22, 911, 1990.
66. (+)-Cl- cotransporter activities in vascular endothelial cells. Am. J. Physiol. 263, H96, 1992.
67. Jurkat-Rott K., Lehmann-Horn F.: The impact of splice isoforms on voltage-gated calcium channel alpha1 subunits. J. Physiol. 554, 609, 2004.
68. 2+ channels. Annu. Rev. Cell Dev. Biol. 16, 521, 2000.
69. Cingolani E., Ramirez Correa G.A., Kizana E., Murata M., Cho H.C., Marban E.: Gene therapy to inhibit the calcium channel beta subunit: physiological consequences and pathophysiological effects in models of cardiac hypertrophy. Circ. Res. 101, 166, 2007.
70. Dolphin A.C.: Beta subunits of voltage-gated calcium channels. J. Bioenerg. Biomembr. 35, 599, 2003.
71. Hering S.: beta-Subunits: fine tuning of Ca(2+) channel block. Trends Pharmacol. Sci. 23, 509, 2002.
72. Jay S.D., Sharp A.H., Kahl S.D., Vedvick T.S., Harpold M.M., Campbell K.P.: Structural characterization of the dihydropyridine-sensitive calcium channel alpha 2-subunit and the associated delta peptides. J. Biol. Chem. 266, 3287, 1991.
73. Klugbauer N., Lacinova L., Marais E., Hobom M., Hofmann F.: Molecular diversity of the calcium channel alpha2delta subunit. J. Neurosci. 19, 684, 1999.
74. 2+ agonists and antagonists. Nature 311, 538, 1984.
75. Cavalie A., Pelzer D., Trautwein W.: Fast and slow gating behaviour of single calcium channels in cardiac cells. Relation to activation and inactivation of calcium-channel current. Pflugers Arch. 406, 241, 1986.
76. Kamp T.J., Hell J.W.: Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ. Res. 87, 1095, 2000.
77. Carmeliet E.: Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol. Rev. 79, 917, 1999.
78. 2+. J. Gen. Physiol. 95, 911, 1990.
79. (2+) current to beta-adrenergic receptor stimulation via a C2 region-containing protein kinase C isoform. Circ. Res. 87, 1164, 2000.
80. 2+ channel alpha1C subunits but does not mediate their sensitivity to acute hypoxia. Biochem. Biophys. Res. Commun. 318, 135, 2004.
81. 2+ Channel Function in the Absence of Apoptosis in Ventricular Myocytes. Circ. Res. 8, 8, 2007.
82. (2+) channels. Circ. Res. 87, 537, 2000.
83. 2+ channels. Cardiovasc. Res. 65, 28, 2005.
84. 2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron 19, 185, 1997.
85. 2+ channel. FEBS Lett. 309, 343, 1992.
86. Seisenberger C., Specht V., Welling A., Platzer J., Pfeifer A., Kuhbandner S., Striessnig J., Klugbauer N., et al.: Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse. J. Biol. Chem. 275, 39193, 2000.
87. Splawski I., Timothy K.W., Decher N., Kumar P., Sachse F.B., Beggs A.H., Sanguinetti M.C., Keating M.T.: Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc. Natl. Acad. Sci. USA 102, 8089, 2005.
88. Antzelevitch C., Pollevick G.D., Cordeiro J.M., Casis O., Sanguinetti M.C., Aizawa Y., Guerchicoff A., Pfeiffer R., et al.: Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 115, 442, 2007.
89. Bodi I., Mikala G., Koch S.E., Akhter S.A., Schwartz A.: The L-type calcium channel in the heart: the beat goes on. J. Clin. Invest. 115, 3306, 2005.
90. Thannickal V.J., Fanburg B.L.: Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L1005, 2000.
91. Nuss H.B., Kaab S., Kass D.A., Tomaselli G.F., Marban E.: Cellular basis of ventricular arrhythmias and abnormal automaticity in heart failure. Am. J. Physiol. 277, H80, 1999.
92. Chen X., Piacentino V., 3rd, Furukawa S., Goldman B., Margulies K.B., Houser S.R.: L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ. Res. 91, 517, 2002.
93. 2+ channels on early afterdepolarizations. Biophys. J. 88, 85, 2005.
94. Abernethy D.R., Schwartz J.B.: Calcium-antagonist drugs. N. Engl. J. Med. 341, 1447, 1999.
95. Herzog W.R., Vogel R.A., Schlossberg M.L., Edenbaum L.R., Scott H.J., Serebruany V.L.: Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size. Int. J. Cardiol. 59, 21, 1997.
96. Muller C.A., Opie L.H., McCarthy J., Hofmann D., Pineda C.A., Peisach M.: Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise. J. Am. Coll. Cardiol. 32, 268, 1998.
97. 2+ exchange in myocardial reperfusion injury in open chest dogs: relative roles during ischemia and reperfusion. Cardiovasc. Res. 36, 337, 1997.
98. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II). Am. J. Cardiol. 66, 779, 1990.
99. Napoli C., Sica V., Pignalosa O., de Nigris F.: New trends in antiatherosclerotic agents. Curr. Med. Chem. 12, 1755, 2005.
100. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N. Engl. J. Med. 319, 385, 1988.
101. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 304, 801, 1981.
102. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247, 1707, 1982.
103. Kendall M.J., Lynch K.P., Hjalmarson A., Kjekshus J.: Beta-blockers and sudden cardiac death. Ann. Intern. Med. 123, 358, 1995.
104. Zhang Z.S., Cheng H.J., Ukai T., Tachibana H., Cheng C.P.: Enhanced cardiac L-type calcium current response to beta2-adrenergic stimulation in heart failure. J. Pharmacol. Exp. Ther. 298, 188, 2001.
105. Hool L.C.: Protein kinase C isozyme selective peptides-a current view of what they tell us about location and function of isozymes in the heart. Curr. Pharm. Des. 11, 549, 2005.
106. Takeishi Y., Jalili T., Ball N.A., Walsh R.A.: Responses of cardiac protein kinase C isoforms to distinct pathological stimuli are differentially regulated. Circ. Res. 85, 264, 1999.
107. Takeishi Y., Ping P., Bolli R., Kirkpatrick D.L., Hoit B.D., Walsh R.A.: Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ. Res. 86, 1218, 2000.
108. Jalili T., Takeishi Y., Song G., Ball N.A., Howles G., Walsh R.A.: PKC translocation without changes in Galphaq and PLC-beta protein abundance in cardiac hypertrophy and failure. Am. J. Physiol. 277, H2298, 1999.
109. (2+) channel alpha(1C) subunit. The initial segment is ubiquitous and crucial for protein kinase C modulation, but is not directly phosphorylated. J. Biol. Chem. 274, 31145, 1999.
110. Hullin R., Khan I.F., Wirtz S., Mohacsi P., Varadi G., Schwartz A., Herzig S.: Cardiac L-type calcium channel beta-subunits expressed in human heart have differential effects on single channel characteristics. J. Biol. Chem. 278, 21623, 2003.
111. 2+ channel expression at the cell surface by the small G-protein kir/Gem. Nature 411, 701, 2001.
112. Murata M., Cingolani E., McDonald A.D., Donahue J.K., Marban E.: Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ. Res. 95, 398, 2004.